The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
Published
April 05, 2021
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
PICOID
cd31cde4
DOI
Citations
8
Keywords
Meta-analysis, Renal function, SGLT2 inhibitors, Safety
Copyright
Copyright © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Patients/Population/Participants
patients with eGFR <60 ml/min/1.73 m
Intervention
SGLT2 inhibitors
Comparison
placebo
Outcome
safety outcomes
Abstract
P
I
C
O
We aimed to assess whether the safety outcomes exerted by sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with different renal function at baseline. We searched randomized controlled trials comparing SGLT2 inhibitors with placebo in participants simultaneously involving the entire range of estimated glomerular filtration rate (eGFR) levels at baseline in one study. According to eGFR, we divided the population into two subgroups with eGFR <60 ml/min/1.73 m The indication of no risk of osmotic diuresis in patients with eGFR<60 ml/min/1.73 m